US: Crackdown on $230 Million Counterfeit Medication Scheme Unveils Global Drug Fraud Crisis

Uncovering the Hernandez counterfeit drug operation sheds light on a burgeoning global crisis, with annual revenues reaching $431 billion. Pharmaceutical giants like Gilead Sciences and Johnson & Johnson are taking a stand against counterfeiters, but stricter regulations are urgently needed to protect public health.

In the underbelly of the pharmaceutical world, a significant counterfeit drug operation has been uncovered, led by the enigmatic Lazaro Hernandez. Orchestrating a $230 million scheme, Hernandez’s operation focused on counterfeiting prescription medications, with a notable emphasis on HIV treatments such as Biktarvy and Descovy. This revelation is not just a standalone incident but a glimpse into a burgeoning global crisis, with counterfeit drugs estimated to rake in up to $431 billion annually, according to the World Health Organization.

The Anatomy of a Counterfeit Operation

Hernandez’s method was both cunning and dangerous. By altering pill bottles and selling them back to pharmacies at lower prices, he turned a massive profit. However, the real horror lies in the deception; some bottles, purported to contain life-saving HIV medication, held Seroquel, an antipsychotic drug, instead. This operation is part of a larger, more disturbing trend. In 2022 alone, the United States witnessed 2,121 incidents of drug counterfeiting, marking a 17% increase from the previous year. The process, known as drug diversion, involves patients selling prescribed medications, which are then altered and sold through a complex chain of buyers, eventually reaching pharmacies.

The Corporate Crusade Against Counterfeits

In response to the growing menace, pharmaceutical giants Gilead Sciences and Johnson & Johnson have taken a stand, filing lawsuits against numerous defendants, including pharmacies and wholesale distributors. These legal battles are not just about financial losses but underscore a dire public health crisis. The counterfeit operations, by altering and selling fake versions of essential drugs, put countless lives at risk. Gilead Sciences stumbled upon the issue when patients began reporting that they received medications different from what was prescribed, lifting the veil on the dangers lurking within the pharmaceutical supply chain.

A Call for Stricter Regulations

The fight against counterfeit drugs is not limited to corporate boardrooms or courtroom battles. A recent study assessing online pharmacies sheds light on a related concern. Out of 116 pharmacies evaluated, 55 were identified as rogue, engaging in practices that flout safety and ethical standards, such as offering refunds for medication without requiring prescriptions. This study, coupled with the Hernandez counterfeit saga, highlights the urgent need for improved regulations governing both legitimate and rogue online pharmacies, especially amidst public health crises.

By Nitish Verma, bnn News Network

Article Link